STOCK TITAN
  1. Home
  2. Sec-filings
  3. KMTS
  4. [Form 4] KESTRA MEDICAL TECHNOLOGIES, LTD. Insider Trading Activity

Kestra Medical (KMTS) CFO sells 18,188 shares to cover RSU taxes

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported sales of 18,188 Common Shares in three transactions on July 30, July 31, and August 3, 2026. The footnotes state these were nondiscretionary sell to cover transactions executed solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with each day’s sales priced at a weighted average within disclosed ranges.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Mahboob Vaseem
Role Chief Financial Officer
Sold 18,188 shs ($418K)
Type Security Shares Price Value
Sale Common Shares F1, F4 5,391 $23.8012 $128K
Sale Common Shares F1, F3 8,817 $22.6091 $199K
Sale Common Shares F1, F2 3,980 $22.7539 $91K
Holdings After Transaction: Common Shares — 93,891 shares (Direct)
Footnotes (4)
  1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
  2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.3300 to $23.0300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
  3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1600 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
  4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6400 to $23.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Total shares sold 18,188 shares Aggregate Common Shares sold by CFO across three reported transactions
Shares sold 2026-07-30 3,980 shares Common Shares sold on 2026-07-30
Weighted average price 2026-07-30 $22.7539 per share Weighted average sale price for 3,980 shares on 2026-07-30
Shares sold 2026-07-31 8,817 shares Common Shares sold on 2026-07-31
Weighted average price 2026-07-31 $22.6091 per share Weighted average sale price for 8,817 shares on 2026-07-31
Shares sold 2026-08-03 5,391 shares Common Shares sold on 2026-08-03
Weighted average price 2026-08-03 $23.8012 per share Weighted average sale price for 5,391 shares on 2026-08-03
Overall price range $22.1600–$23.9800 per share Range of individual trade prices across all three sale dates
sell to cover transactions financial
"represents a nondiscretionary sale of shares required pursuant to sell to cover"
restricted stock units financial
"in connection with the vesting and settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"to satisfy tax withholding obligations in connection with the vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider share sales did Kestra Medical Technologies (KMTS) disclose for its CFO?
Kestra Medical disclosed that CFO Mahboob Vaseem sold 18,188 Common Shares across three transactions. The sales occurred on July 30, July 31, and August 3, 2026, and were tied to tax obligations from vesting restricted stock units rather than discretionary trading.

Were the KMTS CFO’s reported share sales discretionary or for tax purposes?
The filing states the CFO’s sales were nondiscretionary sell to cover transactions. They were required to satisfy tax withholding obligations triggered by the vesting and settlement of restricted stock units, rather than discretionary open-market sales initiated for portfolio or investment reasons.

How many Kestra Medical (KMTS) shares did the CFO sell on each transaction date?
Mahboob Vaseem sold 3,980 shares on July 30, 8,817 shares on July 31, and 5,391 shares on August 3, 2026. All were Common Shares and each transaction is reported with a weighted average sale price and corresponding price range in the footnotes.

At what prices were the KMTS CFO’s shares sold in these Form 4 transactions?
Weighted average prices were $22.7539 per share on July 30, $22.6091 on July 31, and $23.8012 on August 3, 2026. Footnotes note underlying trade prices ranged from $22.1600 to $23.9800 across the different transaction dates.

What explains the KMTS CFO’s need to sell shares according to this Form 4?
According to the footnote, the sales represent nondiscretionary transactions required to cover tax withholding obligations. These obligations arose upon the vesting and settlement of restricted stock units, meaning the CFO sold shares primarily to satisfy tax liabilities from equity compensation.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mahboob Vaseem
(Last)(First)(Middle)
3933 LAKE WASHINGTON BLVD NE, SUITE 200
(Street)
KIRKLAND WASHINGTON 98033
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares07/30/2026S(1)3,980D$22.7539(2)108,099D
Common Shares07/31/2026S(1)8,817D$22.6091(3)99,282D
Common Shares08/03/2026S(1)5,391D$23.8012(4)93,891D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.3300 to $23.0300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1600 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6400 to $23.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR